News Releases Year: - Any -2021202020192018201720162015201420132012 Items per page 102550 11/16/21 Summary ToggleClearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings PDF Version 11/11/21 Summary ToggleClearside Biomedical to Participate in Upcoming Investor Events in November and December 2021 PDF Version 11/10/21 Summary ToggleClearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corporate Update PDF Version 10/28/21 Summary ToggleClearside Biomedical to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Wednesday, November 10, 2021 PDF Version 10/25/21 Summary ToggleBausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis PDF Version 10/13/21 Summary ToggleClearside Biomedical Delivers Podium and Poster Presentations at the American Society of Retina Specialists (ASRS) Annual Meeting PDF Version 10/04/21 Summary ToggleClearside Biomedical Announces Multiple Poster Presentations at the Retina Society 54th Annual Scientific Meeting PDF Version 09/21/21 Summary ToggleClearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients PDF Version 09/09/21 Summary ToggleClearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries PDF Version 08/23/21 Summary ToggleClearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Retina Forum PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Next page Last page Last
